In total, 11 abstracts on givinostat were accepted for presentation at the Congress, including two for an oral presentation ...

Families caring for individuals with Duchenne muscular dystrophy (DMD) face significant financial burdens from necessary home ...

Taiho Pharmaceutical has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy ...

Taiho-developed TAS-205 is designed to selectively inhibit hematopoietic prostaglandin D synthase (HPGDS), an enzyme related ...

Dysfunctional dystrophin, the muscle protein affected in Duchenne, leads to an important choice for patients about how to ...

Sarepta Therapeutics Inc. misled investors about the safety and prospects for one of its Duchenne muscular dystrophy ...

Immune disorders are a leading cause of morbidity and long-term health challenges among children worldwide. Recent decades ...

The deal gives AstraZeneca’s rare disease unit Alexion access to specialized capsids developed by the Japanese biotech JCR ...

New consensus guidelines outline best practices for orthopedic management in Duchenne muscular dystrophy, focusing on ...

The FDA found that data from a single Phase II study were “insufficient” to justify an accelerated approval review for ...

Although only living in the Berkshires for a few years, Evan Butts has already ingrained himself into the community. A server ...